The Court of Appeal partially reversed the Brussels Commercial Court’s decision invalidating Lundbeck’s SPC for escitalopram, to the extent that it had immediate effect.

A summary of this case will be posted on



To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

Kluwer IP Law